Sign In
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- US Share Prices
- Stock Tips
- Share Chat
- FX
- News & RNS
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Shield Thera Share News (STX)
STX Share
Price
STX Share
News
STX Share
Chat
STX Share
Trades54
STX
Live RNS
STX Share
Charts
STX Level 2
Console
STX Live
Share Price
STX Broker
Ratings
STX Directors
Deals
STX Financial
Diary
STX
Fundamentals
STX Short
Positions
STX
Media
STX Company
Research
STX Company
Timeline
Shield Thera Information
Share Price Information for Shield Thera (STX)
Share Price is delayed by 15 minutes
Get Live Data
5.75
-0.10 (-1.71%)
Bid:
5.70
Ask:
5.80
Spread:
0.10 (1.754%)
Market Cap:
£61.50m
Last checked at -
Last checked at 
Intraday Shield Thera Share Chart
Shield Thera News
19 Oct 2020
IN BRIEF: Shield Therapeutics Notes Teva Withdrawing Patent Opposition
IN BRIEF: Shield Therapeutics Notes Teva Withdrawing Patent Opposition
19 Oct 2020
Shield shares rise as Teva withdraws patent oppositions
(Sharecast News) - Commercial-stage pharmaceutical company Shield Therapeutics updated the market on its opposition proceedings with Teva Pharmaceutic...
16 Sep 2020
Shield Therapeutics Swings To Profit As It Makes Feraccru Progress
Shield Therapeutics Swings To Profit As It Makes Feraccru Progress
7 Aug 2020
IN BRIEF: Shield Therapeutics' Product Offers Alternative For Anaemia
IN BRIEF: Shield Therapeutics' Product Offers Alternative For Anaemia
16 Jul 2020
IN BRIEF: Shield Therapeutics Notes PT20 Paper Publication
IN BRIEF: Shield Therapeutics Notes PT20 Paper Publication
26 Jun 2020
UK EXECUTIVE CHANGE SUMMARY: John Menzies Chief Executive Steps Down
UK EXECUTIVE CHANGE SUMMARY: John Menzies Chief Executive Steps Down
11 Jun 2020
UK Shareholder Meetings Calendar - Next 7 Days
UK Shareholder Meetings Calendar - Next 7 Days
3 Jun 2020
Shield Therapeutics shares rise on two recent research papers
(Sharecast News) - Commercial stage pharmaceutical company Shield Therapeutics reported the recent publication of two papers concerning its 'Feraccru'...
Follow the stocks
